Skip to main content

Caligan Partners LP

13F filer · CIK 0001727492
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$2.13BU.S. long equity reported on 13F
Positions255 new · 4 closed
Net flow last quarter+$39.1MBuys minus sells
Top 10 positions weight80.9%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202625 positions
LQDALiquidia Corp$647M30.45%9.11%Not reportedQ4 2022
RVMDRevolution Medicines, Inc.$367M17.28%0.92%+18.7%Q1 2025
ABVXAbivax S.A.$208M9.77%1.98%+6.6%Q4 2024
PCVXVaxcyte, Inc.$127M5.99%1.51%+6.2%Q4 2025
EXELExelixis, Inc.$84.5M3.98%0.62%Not reportedQ1 2023
TNGXTango Therapeutics, Inc.$78.2M3.68%1.48%+3.8%Q4 2025
AVTXAvalo Therapeutics, Inc.$58.5M2.75%5.98%+93.5%Q3 2025
XENEXenon Pharmaceuticals Inc.$53.7M2.53%0.92%-36.1%Q3 2025
ADMAAdma Biologics, Inc.$47.9M2.25%2.54%+20.4%Q4 2022
LBRXLB Pharmaceuticals Inc$46.7M2.20%5.01%Not reportedQ1 2026
IMCRImmunocore Holdings plc$43.9M2.06%2.68%NewQ2 2026
VRDNViridian Therapeutics, Inc.\DE$40.3M1.90%1.94%NewQ2 2026
VORVor Biopharma Inc.$35.4M1.67%3.54%Not reportedQ4 2025
SABSSAB Biotherapeutics, Inc.$31.1M1.46%9.54%Not reportedQ1 2026
IVAInventiva S.A.$30.9M1.45%4.22%+64.1%Q4 2025
AURAAura Biosciences, Inc.$30.5M1.44%4.15%+1769.9%Q2 2025
TYRATyra Biosciences, Inc.$25.8M1.21%1.35%-36.8%Q1 2025
IRDOpus Genetics, Inc.$25M1.17%7.35%0.0%Q1 2026
ANIKAnika Therapeutics, Inc.$21M0.99%10.72%Not reportedQ4 2022
SGMTSagimet Biosciences Inc.$19.3M0.91%8.15%NewQ2 2026
ARTVArtiva Biotherapeutics, Inc.$16.8M0.79%7.02%NewQ2 2026
FTHFaeth Therapeutics, Inc.$15.7M0.74%2.44%+399.6%Q1 2026
MBXMBX Biosciences, Inc.$11M0.52%0.42%-76.4%Q1 2026
VRCAVerrica Pharmaceuticals Inc.$5.65M0.27%5.38%Not reportedQ3 2023
CLRBCellectar Biosciences, Inc.$1.31M0.06%5.70%NewQ2 2026
Q1 2026Reported May 15, 202624 positions
LQDALiquidia Corp$306M20.39%9.19%Not reportedQ4 2022
ABVXAbivax S.A.$163M10.83%1.86%+0.7%Q4 2024
RVMDRevolution Medicines, Inc.$161M10.70%0.83%+28.7%Q1 2025
PCVXVaxcyte, Inc.$120M7.97%1.43%+20.9%Q4 2025
XENEXenon Pharmaceuticals Inc.$81M5.39%1.44%+153.4%Q3 2025
MLYSMineralys Therapeutics, Inc.$75.1M5.00%3.36%Not reportedQ2 2024
EXELExelixis, Inc.$66.6M4.43%0.60%Not reportedQ1 2023
TNGXTango Therapeutics, Inc.$50.4M3.35%1.67%-35.4%Q4 2025
TYRATyra Biosciences, Inc.$48.9M3.25%2.15%+35.2%Q1 2025
SYRESpyre Therapeutics, Inc.$44.3M2.95%1.11%NewQ1 2026
ADMAAdma Biologics, Inc.$42.9M2.85%2.05%+57.9%Q4 2022
LBRXLB Pharmaceuticals Inc$34.6M2.30%5.02%NewQ1 2026
VORVor Biopharma Inc.$34.3M2.29%3.55%+108.1%Q4 2025
SABSSAB Biotherapeutics, Inc.$30.5M2.03%10.52%NewQ1 2026
IRDOpus Genetics, Inc.$27.6M1.84%8.51%NewQ1 2026
IVAInventiva S.A.$27.6M1.84%2.57%+148.8%Q4 2025
MBXMBX Biosciences, Inc.$25.3M1.69%1.78%NewQ1 2026
AVTXAvalo Therapeutics, Inc.$24.4M1.62%6.64%+85.5%Q3 2025
ANIKAnika Therapeutics, Inc.$20.8M1.38%10.74%Not reportedQ4 2022
MAZEMaze Therapeutics, Inc.$18.4M1.22%1.24%+11.8%Q4 2025
VRCAVerrica Pharmaceuticals Inc.$4.89M0.33%5.38%Not reportedQ3 2023
FTHFaeth Therapeutics, Inc.$3.97M0.26%9.40%NewQ1 2026
AURAAura Biosciences, Inc.$1.54M0.10%0.36%Not reportedQ2 2025
XLOXilio Therapeutics, Inc.$943K0.06%1.94%NewQ1 2026
Q4 2025Reported Feb 17, 202620 positions
LQDALiquidia Corp$280M23.05%9.31%Not reportedQ4 2022
ABVXAbivax S.A.$196M16.12%1.85%Not reportedQ4 2024
RVMDRevolution Medicines, Inc.$102M8.42%0.65%+20.6%Q1 2025
MLYSMineralys Therapeutics, Inc.$101M8.28%3.40%Not reportedQ2 2024
PCVXVaxcyte, Inc.$78.7M6.48%1.30%NewQ4 2025
EXELExelixis, Inc.$68.1M5.60%0.58%+1.8%Q1 2023
ADMAAdma Biologics, Inc.$54.9M4.52%1.27%+14.3%Q4 2022
TNGXTango Therapeutics, Inc.$33M2.72%2.74%NewQ4 2025
INBXInhibrx Biosciences, Inc.$25.6M2.10%2.22%+36.9%Q3 2025
TYRATyra Biosciences, Inc.$24.8M2.04%1.76%+35.5%Q1 2025
XENEXenon Pharmaceuticals Inc.$24.6M2.03%0.69%+23.6%Q3 2025
MAZEMaze Therapeutics, Inc.$22.8M1.88%1.12%NewQ4 2025
RAPTRAPT Therapeutics, Inc.$21.8M1.80%2.33%NewQ4 2025
AVTXAvalo Therapeutics, Inc.$16M1.32%4.76%+5.8%Q3 2025
ANIKAnika Therapeutics, Inc.$13.8M1.14%10.33%Not reportedQ4 2022
VORVor Biopharma Inc.$9.96M0.82%2.39%NewQ4 2025
IVAInventiva S.A.$9.3M0.77%1.04%NewQ4 2025
VRCAVerrica Pharmaceuticals Inc.$7.68M0.63%5.38%Not reportedQ3 2023
SPRBSpruce Biosciences, Inc.$1.79M0.15%1.50%NewQ4 2025
ELDNEledon Pharmaceuticals, Inc.$840K0.07%0.74%NewQ4 2025
Q3 2025Reported Nov 14, 202516 positions
LQDALiquidia Corp$185M24.18%9.35%Not reportedQ4 2022
ABVXAbivax S.A.$123M16.14%2.29%-13.3%Q4 2024
MLYSMineralys Therapeutics, Inc.$105M13.77%3.51%+37.4%Q2 2024
EXELExelixis, Inc.$63M8.25%0.57%Not reportedQ1 2023
RVMDRevolution Medicines, Inc.$49.7M6.51%0.56%+67.1%Q1 2025
AGIOAgios Pharmaceuticals, Inc.$45.4M5.95%1.94%+5.6%Q4 2022
ADMAAdma Biologics, Inc.$38.7M5.06%1.11%Not reportedQ4 2022
EOLSEvolus, Inc.$25.4M3.33%6.39%+23.9%Q4 2022
MRUSMerus N.V.$20.4M2.68%0.29%-67.0%Q4 2024
XENEXenon Pharmaceuticals Inc.$17.8M2.34%0.58%NewQ3 2025
ANIKAnika Therapeutics, Inc.$13.5M1.77%9.95%Not reportedQ4 2022
AVTXAvalo Therapeutics, Inc.$10.6M1.39%4.67%NewQ3 2025
TYRATyra Biosciences, Inc.$9.75M1.28%1.31%+266.9%Q1 2025
INBXInhibrx Biosciences, Inc.$7.96M1.04%1.63%NewQ3 2025
VRCAVerrica Pharmaceuticals Inc.$3.98M0.52%9.74%0.0%Q3 2023
AURAAura Biosciences, Inc.$1.4M0.18%0.36%+13.6%Q2 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.